Immunome INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

19 Mar 2025

IMNM

10-K: Immunome Reports 2024 Annual Results, Highlights Clinical Pipeline Progress

Immunome, a clinical-stage oncology company, provides an update on its financial results for the year ended December 31, 2024, and outlines key advancements in its targeted therapy development programs.

NASDAQ

28 Mar 2024

IMNM

Immunome INC

10-K: Immunome Finalizes Executive Separation, Outlines Future Strategy in 10-K Filing

Immunome's 10-K filing details a separation agreement with a former executive, while also providing insights into the company's strategic direction and pipeline.